Friday, June 16, 2023 9:20:23 AM
HANOVER, MD, June 14, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that CEO David Young, Pharm.D., Ph.D. will present at the MedInvest Oncology Investor Conference being held on June 21-22, 2023 in Boston, MA.
Dr. Young’s presentation, titled “Next Generation Chemotherapy to Improve Treatment of Cancer while Treating More Patients,” will be held on June 21, 2023 at 12:00pm ET.
Dr. Young will also provide a corporate overview of Processa and will be available for 1 x 1 investor meetings during the conference. To schedule a meeting, please contact: dyoung@processapharma.com.
About Processa Pharmaceuticals, Inc.
Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy (NGC) drugs following an efficient path to approval. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. The Processa team has a track record of obtaining over 30 approvals for indications across almost every division of FDA. Using its proven Regulatory Science Approach, the Processa Team has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response and a greater number of patients -- in excess of 200,000 for each NGC drug -- who will benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers).
For more information, visit our website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Investors:
Bret Shapiro
CORE IR
ir@processapharma.com
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
https://www.bing.com/ck/a?!&&p=9e9c5561c3de4b99JmltdHM9MTY4Njg3MzYwMCZpZ3VpZD0zNjY2ZDA0YS1mMmI3LTY3NTQtM2I3NS1jMDFkZjM5YjY2OWImaW5zaWQ9NTI3Ng&ptn=3&hsh=3&fclid=3666d04a-f2b7-6754-3b75-c01df39b669b&psq=Processa+Pharmaceuticals+Inc&u=a1aHR0cHM6Ly9zdG9ja2hvdXNlLmNvbS9uZXdzL3ByZXNzLXJlbGVhc2VzLzIwMjMvMDYvMTQvbmV4dC1nZW5lcmF0aW9uLWNoZW1vdGhlcmFweS1pbXByb3ZlZC10cmVhdG1lbnQtZm9yLW1vcmUtcGF0aWVudHM&ntb=1
Only Free Men Own Guns
Recent PCSA News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:13:45 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/21/2024 08:10:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:16:05 PM
- Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:15:00 PM
- Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 03/25/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 01:15:00 PM
- Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference • GlobeNewswire Inc. • 02/14/2024 06:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:30:35 PM
- Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 11:32:03 PM
- Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering • GlobeNewswire Inc. • 02/01/2024 09:22:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 03:46:33 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/29/2024 09:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/29/2024 05:15:11 AM
- Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering • GlobeNewswire Inc. • 01/26/2024 02:04:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:35:27 PM
- Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 01:00:12 PM
- Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer • GlobeNewswire Inc. • 01/19/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:30:13 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM